The Goldman Sachs Group Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $43.00

Day One Biopharmaceuticals (NASDAQ:DAWN) had its target price reduced by The Goldman Sachs Group from $48.00 to $43.00 in a research report sent to investors on Monday morning,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

A number of other research analysts have also commented on the company. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Needham & Company LLC restated a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, January 13th. Finally, Bank of America dropped their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Price Performance

DAWN stock opened at $12.13 on Monday. The company has a 50-day moving average of $12.52 and a two-hundred day moving average of $13.57. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -11.78 and a beta of -1.46. Day One Biopharmaceuticals has a 52-week low of $11.13 and a 52-week high of $18.07.

Insider Activity

In other news, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total value of $399,300.00. Following the sale, the insider now owns 1,034,015 shares in the company, valued at approximately $13,762,739.65. The trade was a 2.82 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. R Squared Ltd bought a new position in shares of Day One Biopharmaceuticals in the fourth quarter valued at approximately $31,000. Mirae Asset Global Investments Co. Ltd. grew its position in Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after acquiring an additional 1,002 shares during the last quarter. Quest Partners LLC increased its holdings in Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after purchasing an additional 7,668 shares in the last quarter. E Fund Management Co. Ltd. acquired a new stake in Day One Biopharmaceuticals during the 4th quarter valued at $143,000. Finally, KLP Kapitalforvaltning AS acquired a new position in Day One Biopharmaceuticals in the fourth quarter worth $150,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.